Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081792 | 0.86 | TSHR (0.31) | TSHRMAPK1 | |
| SCHEMBL5078678 | 0.83 | TSHR (0.31) | TSHRMAPK1 | |
| SCHEMBL5077731 | 0.82 | TSHR (0.35) | TSHRMAPK1 | |
| SCHEMBL5078187 | 0.78 | TSHR (0.33) | TSHRMAPK1 | |
| SCHEMBL1276341 | 0.78 | TSHR (0.40) | TSHRMAPK1 | |
| SCHEMBL5075125 | 0.77 | NUDT1 (0.31) | — | |
| SCHEMBL5078222 | 0.76 | TSHR (0.30) | TSHRMAPK1 | |
| SCHEMBL5081610 | 0.75 | TSHR (0.31) | TSHRMAPK1 | |
| SCHEMBL5080958 | 0.74 | — | — | |
| SCHEMBL3317229 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399812-B2 | Silicon ether compounds and a method for the preparation thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-07-15 | — | — | US | claimed |
| US-7323431-B2 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-01-29 | — | — | US | claimed |
| US-20060183873-A1 | Silicon ether compounds and a method for the preparation thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-08-17 | — | — | US | claimed |
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | claimed |
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-1591446-B1 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8058280-B2 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-15 | — | — | US | disclosed |
| US-7399812-B2 | Silicon ether compounds and a method for the preparation thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-07-15 | — | — | US | disclosed |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7323431-B2 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-01-29 | — | — | US | disclosed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060183873-A1 | Silicon ether compounds and a method for the preparation thereof | BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-08-17 | — | — | US | disclosed |
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20060142146-A1 | Catalyst for olefin polymerization and use of the same | CHINA PETROLEUM & CHEMICAL CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1591446-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | TSHR 77/4885MAPK1 907/4885 |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | TSHR 15/4885MAPK1 2016/4885 |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | TSHR 77/4885MAPK1 907/4885 |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | TSHR 15/4885MAPK1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.